TELA Bio Reports Record Q4 Revenue but Misses Sales Estimates; Shares Dip
TELA Bio Inc (NASDAQ:TELA), a commercial-stage medical technology company, announced its financial results for the fourth quarter and full year ended December 31, 2025. The company posted its strongest quarterly revenue on record, though the top-line figure came in slightly below Wall Street expectations. The market's initial reaction was negative, with shares trading lower in the after-hours session following the report.
Earnings and Revenue Versus Estimates
The core financial metrics for the quarter presented a mixed picture. TELA Bio reported a net loss of $9.0 million, or $0.17 per share, an improvement from a net loss of $9.2 million, or $0.23 per share, in the prior-year period. On a non-GAAP basis, the loss per share was $0.16, which was notably better than the analyst consensus estimate for a loss of $0.1863 per share.
However, the company's revenue of $20.9 million, while representing an 18% year-over-year increase, fell short of the analyst estimate of $21.47 million. This miss on the top line appears to be the primary driver behind the negative after-market price action, overshadowing the better-than-expected bottom-line performance.
Key Financial and Operational Highlights
The earnings release highlighted several important developments for TELA Bio as it closed out its fiscal year:
- Record Quarterly Revenue: Q4 2025 revenue of $20.9 million marked a company record, driven by new customer additions, the U.S. launch of a larger OviTex PRS product configuration, and growth in international sales.
- Improved Profitability Metrics: Gross margin expanded to 65.9% in the quarter, up from 63.6% in Q4 2024, primarily due to lower inventory-related charges. For the full year, the company held operating expenses essentially flat at $88.1 million despite delivering 16% revenue growth to $80.3 million, demonstrating operating leverage.
- Strengthened Commercial Team: The company expanded its sales force to 88 quota-carrying representatives and expressed confidence in this team to drive deeper market penetration.
- Secured Financing: TELA Bio closed on a new credit facility for up to $70 million from Perceptive Advisors, providing additional financial flexibility. The company ended the year with $50.8 million in cash and cash equivalents.
Forward Guidance and Analyst Expectations
Management provided financial guidance for the coming year, projecting at least 8% revenue growth for the full year 2026 over the 2025 total of $80.3 million. This implies 2026 revenue of approximately $86.7 million or higher.
- Company's Q1 2026 Guidance: Approximately $18.5 million in revenue.
- Analyst Consensus for Q1 2026: $21.70 million in revenue and a loss per share of $0.164.
- Analyst Consensus for Full-Year 2026: $94.53 million in revenue and a loss per share of $0.598.
The company's provided outlook for both the first quarter and the full year is currently below the consensus analyst estimates, which likely contributed to the cautious market reaction. CEO Antony Koblish stated the guidance reflects confidence in the team's ability to deliver growth "without the need to raise additional capital," emphasizing a path to profitability.
Market Reaction and Summary
The market's negative response, with shares down in after-hours trading, can be attributed to the revenue miss for Q4 and the conservative nature of the company's 2026 revenue guidance compared to analyst expectations. While the improved gross margin and better-than-expected non-GAAP EPS are positive signs of operational efficiency, investors appear focused on the pace of top-line growth.
In summary, TELA Bio's quarter showed solid execution on cost control and bottom-line improvement, but questions about the trajectory of sales growth in the near term are tempering enthusiasm. The company is betting on its expanded commercial team to drive market penetration and meet its growth targets.
For a detailed look at historical earnings and future analyst projections, you can review the TELA earnings history and analyst forecast data.
Disclaimer: This article is for informational purposes only and does not constitute investment advice, financial advice, or a recommendation to buy or sell any security. Investors should conduct their own research and consult with a qualified financial advisor before making any investment decisions.